GlassScriptPhysician profile
Richard Brouette
NPI 1942299342
$813.30
in general payments reported to CMS, 2019-2025
14 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.16 · 2021: $15.28 · 2022: $374 · 2023: $136 · 2024: $153 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $325.36 | 2022-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $132.70 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lilly USA, LLC | $64.02 | 2022-2024 | Jardiance, Zepbound |
| Amgen INC. | $56.46 | 2022-2024 | Otezla, Repatha |
| Verity Pharmaceuticals INC. | $41.33 | 2024 | Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $28.93 | 2023 | |
| Lundbeck LLC | $26.59 | 2024 | Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.07 | 2022 | |
| Neurocrine Biosciences, INC. | $21.25 | 2025 | |
| Amarin Pharma, INC. | $20.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.48 | 2025 | Uzedy |
| Glaxosmithkline, LLC. | $16.84 | 2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $15.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Brouette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.